Time | Grand Ballroom 1 | Grand Ballroom 2 & 3 | Grand Ballroom 4 | Green Room | Child | |||
---|---|---|---|---|---|---|---|---|
14:00 – 18:00 | INHSU Hepatitis C Point-of-Care Testing Forum (Green Room 11) |
Time | Grand Ballroom 1 | Grand Ballroom 2 & 3 | Grand Ballroom 4 | Green Room | Child | |||
---|---|---|---|---|---|---|---|---|
10:30 – 12:30 | Symposium pré meeting AFEF/ANRS | |||||||
12:15 – 13:15 | Industry Lunch Symposium | |||||||
13:15 – 13:30 | ||||||||
13:30 – 14:00 | GHS 2023 OPENING REMARKS | |||||||
14:00 – 16:00 | PLENARY 1 | |||||||
16:00 – 16:15 | AWARDS CEREMONY | |||||||
16:15 – 16:30 | PM BREAK | |||||||
16:30 – 17:50 | Basic 1 | Public Health 1 | Clinical 1 | Clinical 3 | ||||
17:50 – 18:20 | Basic 1 | Public Health 1 | Clinical 3 | |||||
18:05 – 18:35 | Basic 1 | Clinical 3 | ||||||
18:35 – 18:50 | Basic 1 | |||||||
18:30 – 20:30 | Welcome Reception Exhibit Hall |
Time | Grand Ballroom 1 | Grand Ballroom 2 & 3 | Grand Ballroom 4 | Green Room | Child | |||
---|---|---|---|---|---|---|---|---|
08:30 – 10:30 | Basic 5 | EASL-AASLD Joint Symposium 1 | Public Health 4 | Clinical 11 | ||||
10:30 – 10:35 | Basic 5 | Public Health 4 | Clinical 11 | |||||
10:35 – 10:50 | Public Health 4 | |||||||
10:30 – 11:00 | AM BREAK | |||||||
11:00 – 13:00 | PLENARY 2 | |||||||
13:00 – 14:00 | LUNCH BREAK & INDUSTRY SATELLITE | Industry Lunch Symposium | ||||||
14:00 – 14:15 | EASL/AASLD 2 | Clinical 2 | Debate 1 | |||||
14:15 – 15:50 | Basic 6 | EASL/AASLD 2 | Clinical 2 | Debate 1 | ||||
15:50 – 16:00 | EASL/AASLD 2 | Debate 1 | ||||||
16:00 – 16:05 | ||||||||
16:00 – 16:30 | PM BREAK | |||||||
16:30 – 17:50 | Clinical 12 | Basic 2 + 4 | Public Health 2 | Clinical 7 | ||||
17:50 – 18:20 | Clinical 12 | Basic 2 + 4 | Public Health 2 | |||||
18:10 – 18:35 | Basic 2 + 4 | Public Health 2 | ||||||
18:30 – 18:40 | Basic 2 + 4 | |||||||
18:30 – 20:00 | Industry Evening Symposium |
Time | Grand Ballroom 1 | Grand Ballroom 2 & 3 | Grand Ballroom 4 | Green Room | Green Room 10 | Child | ||||
---|---|---|---|---|---|---|---|---|---|---|
08:30 – 09:50 | WHO SYMPOSIUM | Basic 7 | Clinical 4 | Basic 9 | ||||||
09:50 – 10:05 | WHO SYMPOSIUM | Basic 7 | Clinical 4 | |||||||
10:05 – 10:20 | WHO SYMPOSIUM | Clinical 4 | ||||||||
10:20 – 10:30 | WHO SYMPOSIUM | |||||||||
10:30 – 10:45 | AM BREAK | |||||||||
10:45 – 11:00 | JOHN C. MARTIN TRIBUTE by Michael Manns (Germany) (10:45 – 11:00) | |||||||||
11:00 – 13:00 | PLENARY 3 – New vaccine approaches for liver diseases | |||||||||
13:00 – 14:00 | LUNCH BREAK & INDUSTRY SATELLITE | Industry Lunch Symposium | ||||||||
14:00 – 14:15 | Basic 3 | Public Health 3 | Debate 2 | |||||||
14:15 – 15:05 | Clinical 9 | Basic 3 | Public Health 3 | Debate 2 | ||||||
15:05 – 16:00 | Basic 3 | Public Health 3 | Debate 2 | |||||||
16:00 – 16:05 | Basic 3 | Public Health 3 | ||||||||
16:00 – 16:20 | #rowspan# | Public Health 3 | ||||||||
16:00 – 16:30 | PM BREAK | |||||||||
16:30 – 17:50 | Late-Breaker Abstracts Session | Basic 8 | Clinical 10 | Clinical 8 | NoHep Medical Visionaries Symposium | |||||
17:50 – 18:30 | Late-Breaker Abstracts Session | Basic 8 | Clinical 8 | NoHep Medical Visionaries Symposium | ||||||
18:30 – 18:35 | Clinical 8 |
Organizer
MCI Canada
1166 Alberni St #504,
Vancouver, BC V6E 1A5, Canada
GHSinfo@mci-agency.com
Cookie | Duration | Description |
---|---|---|
cookielawinfo-checkbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
cookielawinfo-checkbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
cookielawinfo-checkbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |
Country perspectives – HCV self-testing: Saeed Hamid (Pakistan)
Implementing partner: Oriel Fernandez (CHAI)
Community perspectives: Su Wang, World Hepatitis Alliance (WHA)
The financing gap: Finn Jarle Rode/Maria Salazar, (The Hepatitis Fund (THF))
Coordinated public health responses from Countries: John Ward (CGHE)
Data to measure and drive progress: Homie Razavi (CDA Foundation)
Presented by
Title: GSK Looking to the future of hepatitis B: Why should we aim for functional cure?
Join our esteemed panel of experts to explore the real-world unmet needs for people living with chronic hepatitis B and understand the potential impact the advent of functional cure could have at the level of everyday patient care.
Speakers:
Danjuma Adda is a Hepatitis B patient, advocate and a voice for poor populations. He was infected with Hep B while in clinical rotations and then lost his own mother to the disease several years later. He has a background in microbiology, and an MPH, with over 15 years-experience in public health and advocacy. Danjuma in 2021 assumed the role of President, World Hepatitis Alliance (WHA), UK. His local charity in Nigeria also works in the area of HIV/AIDS prevention and care, patient safety and antimicrobial resistance and stewardship in Nigeria, working to raise awareness and health care worker’s education to reduce the burden of antimicrobial resistance in Nigeria. Danjuma is a Senior Fellow with ASPEN Institute, US; Technical Advisor/Member of the World Health Organizations (WHO) Strategic and Advisory Committee on HIV, Viral Hepatitis and STIs (STAC-HHS); Executive Board Member Coalition for Global Hepatitis Elimination (CGHE) at the Global Task Force for Hepatitis US CDC; Member AMR Advisory Group of the AMR Patient Alliance; and member of several global networking groups and an accomplished Public Speaker. Danjuma is a leading voice for Hepatitis patients in Nigeria and uses his platform to advocate for the most vulnerable populations across Africa. Danjuma wants to change the narrative about Hepatitis and raise awareness about the deadliness of the disease, while also promoting other health outcomes such as antimicrobial stewardship and patient safety.
Dr Chari Cohen is President of the Hepatitis B Foundation. For the past 22 years, she has planned, implemented and evaluated community programs and research projects focusing on reducing health disparities and improving health outcomes associated with hepatitis B and liver cancer. Dr. Cohen is co-chair of the national Hep B United coalition, co-founder and chair of Hep B United Philadelphia, co-founder and chair of CHIPO: Coalition Against Hepatitis for People of African Origin; co-chair of the Hep Free PA coalition; and chair of the Sidney Kimmel Cancer Center Community Advisory Board. She is a member of the ICE-HBV steering committee, the HepVu advisory committee, and is a member of the HBV Forum for Collaborative Research and the Patient Advocacy Group of the American Association for the Study of Liver Diseases (AASLD). Dr. Cohen is Professor at the Baruch S. Blumberg Institute, and adjunct faculty for Geisinger Commonwealth School of Medicine. She received her DrPH in Community Health and Prevention from Drexel University and her MPH from Temple University.
Dr Ahmed El Sharkawy has been a consultant transplant hepatologist at the Queen Elizabeth Hospital in Birmingham since 2012. He is also honorary senior lecturer at the University of Birmingham and a Fellow of the Royal College of Physicians of London. His clinical interests include viral hepatitis, liver transplantation, polycystic liver disease, drug induced liver injury, primary biliary cholangitis, acute liver failure, acute on chronic liver failure, NAFLD (especially in the context of hepatitis B) and cirrhotic sarcopaenia. He has pioneered novel approaches to the management of hepatitis C in the community. He was awarded his PhD from Newcastle University on the role of NF-kB in the hepatic inflammation-fibrosis-cancer axis. He is a research active NHS clinician and is PI on a number of trials including a NIHR Liver Research Partnership on HBV Patient Engagement. He is the EASL Internal Affairs Councillor, Treasurer of BASL and Clinical Lead of the BASL HBV SiG. He is keen on promoting the role of social media, in particular Twitter, in medical education.
Professor Victor de Lédinghen MD PhD is Professor of Hepatology and is currently Head of the Hepatology and Liver Transplantation Unit, Haut Lévêque Hospital, University Hospital of Bordeaux, Pessac, France. Victor de Lédinghen graduated at Bordeaux University, and Cornell University (New York, USA) with a Hepato-Gastroenterology Degree and Medical Degree in 1993, and PhD in 2001. In 2003, he became Professor in Hepatology at the University Hospital of Bordeaux, France. Professor de Lédinghen has a long-standing interest in the non-invasive diagnosis of liver fibrosis and chronic liver diseases, and runs a clinical research programme studying the natural history of liver fibrosis, its impact upon patients and novel therapies for chronic liver diseases associated with liver fibrosis. His hepatology unit is the reference centre for all rare chronic liver diseases (PBC, PSC, Wilson’s disease…) in Nouvelle-Aquitaine (France). He supervises the clinical research programme of new drugs for nonalcoholic steatohepatitis (NASH) and HBV/HDV infection. His research has included participation in national and international HBV, HCV and NAFLD clinical trials, and had led to the publication of more than 300 articles in peer-reviewed journals. He supervises HBV HCV elimination in a large project “Bordeaux Metropolis without viral hepatitis”. He is a member of the European Association for the Study of the Liver, and the American Association for the Study of Liver Diseases. He is former Secretary General of the French Association for the Study of Liver Diseases (AFEF)
Associate Professor Thomas Tu is a molecular biologist and leads a research group at the Westmead Institute for Medical Research in the Storr Liver Centre (Sydney, Australia), where his team focuses on persistent forms of the Hepatitis B virus (covalently closed circular DNA and integrated HBV DNA) and develops methods to measure and eliminate them. He is particularly passionate about developing an HBV cure and mitigating the associated liver cancer, as he himself lives with chronic Hepatitis B. This provides him with unique perspectives on the disease as a researcher, patient, and advocate. He has won multiple awards for his research and outreach, most recently the 2022 Young Tall Poppy Science award. A/Prof Tu is President of the Australian Centre for Hepatitis Virology, the premier Australian society for hepatitis virus researchers. He is also the founder and Director of HepBCommunity.org (a global support network for people affected with HBV), guiding people through their HBV diagnosis, and linking them with trustworthy scientific and medical information. Recently he has established Hepatitis B Voices Australia, an advocacy group run by the affected community.
Date and Time: Tuesday, April 25 12:15 – 13:15
Location: Grand Ballroom 1
Professor Margaret Hellard AM is a Deputy Director at the Burnet Institute, Head of Hepatitis Services in Department of Infectious Diseases at The Alfred Hospital and an Adjunct Professor at Monash University and University of Melbourne, Melbourne, Australia. Margaret is an infectious disease physician, public health physician and infectious diseases epidemiologist (and yes was one prior to COVID), with her work focusing on the management of blood borne viruses; the ultimate aim being to eliminate viral hepatitis as a public health threat and end the HIV/AIDS epidemic. A key aspect of this work is to ensure equity of access to all people at risk of blood borne viruses, including people who inject drugs. Since the COVID pandemic, Margaret has continued her blood borne virus work, whilst also undertaking modelling, public health and epidemiology studies aimed at reducing the direct and indirect impacts of the COVID-19 epidemic on the community. Again a focus is ensuring health and social equity for groups at greater risk of COVID infections and the public health responses aimed at reducing COVID. Margaret is a member of numerous advisory committees and working groups on viral hepatitis and HIV within Australia and globally, including Co-Chairing the WHO Strategic and Technical Advisory Group on HIV, Viral Hepatitis and STIs.
Stéphane Chevaliez is Professor of Medicine at the University of Paris-Est in Paris. He is also Director of the National Reference Center for Viral Hepatitis B, C and delta, a medical virologist in the department of Virology, and a member of INSERM Unit U955. Professor Chevaliez earned his pharmacy degree and PhD in virology at the University of Paris-Saclay and at the Pasteur Institute in Paris. Subsequently, he completed a postdoctoral fellowship in the Department of Gastroenterology and Hepatology at Massachusetts General Hospital, Boston, USA. Professor Chevaliez’s research interests include the diagnosis and virological monitoring of chronic viral hepatitis, and the development of novel therapeutic treatments. More recently he has focused on the molecular mechanisms underlying the success and failure (including viral resistance) of HBV, HCV and HDV treatment, as well as the development of alternative approaches to venous puncture for screening and diagnosis of viral hepatitis. Professor Chevaliez is the President of the Concerted Action 43 of the French National Agency for Research on AIDS and viral Hepatitis (ANRS-MIE).
Prof Jeffrey V. Lazarus (PhD, MIH, MA) is the head of the Health Systems Research Group at ISGlobal and Associate Professor at the University of Barcelona as well as a senior scholar at the CUNY Graduate School of Public Health and Health Policy. He is well known for his work on people-centred health systems and for launching the micro-elimination approach in hepatitis C elimination efforts. He currently serves as co-chair of the HIV Outcomes Beyond Viral Suppression coalition, a member of the board of directors of the SHARE Global Health Foundation and as a member of the EASL Public Health and Policy Committee and the Global NASH Council and is part of the ICE-HBV, ACHIEVE (in Europe) and AEHVE (in Spain) viral hepatitis elimination coalitions as well as the technical advisory group of Coalition for Global Hepatitis Elimination.
Sunil Suhas Solomon, MBBS PhD MPH is an Associate Professor of Medicine and Epidemiology in the Division of Infectious Diseases at the Johns Hopkins University School of Medicine. He completed his medical training at the Sri Ramachandra Medical University in Chennai, India and received a Masters in Public Health and a doctorate in Epidemiology (PhD) from the Johns Hopkins University, USA. Dr. Solomon has been elected into the Phi Beta Kappa and the Delta Omega honors societies. His research is primarily focused on the epidemiology, clinical management and access to care for HIV and viral hepatitis among vulnerable populations including people who inject drugs and men who sex with men. He has been working with PWID in India since 2004 and has over 140 original peer-reviewed publications in several high-ranked journals.
Maud Lemoine is Professor and Consultant of Hepatology at St Mary’s hospital, Imperial College London. She is leading a research programme on prevention and management of chronic hepatitis B in Africa (www.prolifica.africa)